TRBC1/TRBC2 Antibodies for Fixed-Tissue Clonality Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for T-cell malignancies are ineffective and immunotherapies are limited due to the overlap in marker expression between clonal and normal T-cells, leading to severe immunosuppression and toxicity, and there is a lack of diagnostic agents to determine TRBC1/TRBC2 clonality in fixed tissue samples.
Innovation Solution
Development of TRBC1 and TRBC2-specific antibodies that can be used to investigate T-cell clonality in fresh, frozen, or fixed tissue samples, allowing for targeted therapy by administering TRBC1- or TRBC2-specific therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-T-cell depletion therapy is used to treat T-cell malignancy, then malignant T-cells are eliminated, but severe immunosuppression and toxicity occur due to depletion of healthy T-cells
Solution Approach 1:
The patent segments the T-cell population by targeting specific TRBC1 or TRBC2 subtypes rather than depleting all T-cells uniformly. This allows selective elimination of malignant T-cells expressing one TRBC subtype while preserving healthy T-cells expressing the other TRBC subtype, thereby reducing immunosuppression and toxicity.
Solution Approach 2:
The invention applies local quality by targeting specific molecular characteristics (TRBC1 or TRBC2) present only in malignant T-cells rather than applying blanket depletion. This localized targeting approach eliminates malignancy while preserving the functional T-cell compartment, addressing the harmful effects of broad immunosuppression.
2Object-affected harmful factors
If TRBC1 or TRBC2-specific therapy is used, then healthy T-cells are preserved, but diagnostic agents are needed to determine clonality in fixed tissue samples
Solution Approach 1:
The patent employs TRBC1 and TRBC2-specific antibodies as intermediary diagnostic tools. These antibodies serve as mediators that enable detection of TRBC expression patterns in fixed tissue samples through immunohistochemistry, allowing clonality determination without requiring complex molecular techniques.
Solution Approach 2:
The invention utilizes colorimetric detection through immunohistochemical staining with TRBC1 and TRBC2-specific antibodies. The color change signal from the staining process enables visual identification and quantification of TRBC expression patterns in fixed tissue, simplifying the detection process for clonality assessment.
3Productivity
If conventional chemotherapy is used for T-cell malignancy, then some malignancy reduction is achieved, but treatment is ineffective and highly toxic
Solution Approach 1:
The patent replaces conventional chemotherapy (non-specific cytotoxic mechanism) with targeted immunotherapy using TRBC1 or TRBC2-specific antibodies. This substitution of mechanism allows for selective elimination of malignant T-cells through antigen-specific recognition, achieving malignancy reduction with significantly reduced toxicity compared to non-specific chemotherapy.
Data Source
AI summary
The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.